Oscar Health, Inc. (NYSE:OSCR) Shares Bought by Rhumbline Advisers

Rhumbline Advisers increased its holdings in Oscar Health, Inc. (NYSE:OSCR) by 8.7% during the 2nd quarter, HoldingsChannel reports. The fund owned 270,341 shares of the company’s stock after acquiring an additional 21,717 shares during the quarter. Rhumbline Advisers’ holdings in Oscar Health were worth $4,277,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of OSCR. American International Group Inc. lifted its position in shares of Oscar Health by 1.3% during the first quarter. American International Group Inc. now owns 79,411 shares of the company’s stock worth $1,181,000 after purchasing an additional 1,009 shares during the last quarter. ProShare Advisors LLC boosted its holdings in Oscar Health by 10.9% in the first quarter. ProShare Advisors LLC now owns 28,950 shares of the company’s stock worth $430,000 after purchasing an additional 2,842 shares during the period. Oppenheimer & Co. Inc. increased its stake in Oscar Health by 20.8% during the first quarter. Oppenheimer & Co. Inc. now owns 19,450 shares of the company’s stock valued at $289,000 after purchasing an additional 3,350 shares during the last quarter. Avalon Trust Co acquired a new stake in shares of Oscar Health during the first quarter worth $69,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Oscar Health by 26.9% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,210 shares of the company’s stock valued at $383,000 after buying an additional 5,138 shares during the period. Hedge funds and other institutional investors own 75.70% of the company’s stock.

Insiders Place Their Bets

In related news, CAO Victoria Baltrus sold 4,226 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $17.99, for a total transaction of $76,025.74. Following the completion of the transaction, the chief accounting officer now owns 140,648 shares of the company’s stock, valued at $2,530,257.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CFO Richard Scott Blackley sold 29,957 shares of the business’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $17.06, for a total transaction of $511,066.42. Following the sale, the chief financial officer now directly owns 853,875 shares of the company’s stock, valued at $14,567,107.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Victoria Baltrus sold 4,226 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $17.99, for a total value of $76,025.74. Following the completion of the transaction, the chief accounting officer now owns 140,648 shares of the company’s stock, valued at approximately $2,530,257.52. The disclosure for this sale can be found here. In the last three months, insiders have sold 169,569 shares of company stock worth $3,007,069. 25.11% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

OSCR has been the topic of a number of recent research reports. Robert W. Baird started coverage on shares of Oscar Health in a report on Thursday, May 30th. They issued an “outperform” rating and a $28.00 target price on the stock. Baird R W raised Oscar Health to a “strong-buy” rating in a report on Thursday, May 30th. Bank of America restated a “neutral” rating and set a $21.00 price objective (down previously from $25.00) on shares of Oscar Health in a research report on Thursday, May 30th. Wells Fargo & Company increased their target price on Oscar Health from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 12th. Finally, Piper Sandler reissued an “overweight” rating and set a $28.00 price target on shares of Oscar Health in a report on Tuesday, September 10th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.17.

Oscar Health Trading Up 1.4 %

Shares of Oscar Health stock opened at $21.92 on Tuesday. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.26. Oscar Health, Inc. has a 1-year low of $4.72 and a 1-year high of $23.44. The business’s fifty day moving average price is $17.39 and its two-hundred day moving average price is $17.38.

Oscar Health (NYSE:OSCR) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.04. The business had revenue of $2.20 billion for the quarter, compared to analysts’ expectations of $2.13 billion. Oscar Health had a net margin of 0.25% and a return on equity of 1.86%. The company’s revenue was up 44.6% on a year-over-year basis. During the same period in the previous year, the business earned ($0.07) earnings per share. As a group, equities research analysts anticipate that Oscar Health, Inc. will post 0.01 EPS for the current fiscal year.

About Oscar Health

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.